Literature DB >> 26320625

Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents.

Shaoyong Ke1, Liqiao Shi2, Ziwen Yang2.   

Abstract

A series of isatin-dehydroepiandrosterone hybrids were synthesised via a convenient condensation procedure, and which were evaluated for their potential anticancer activities. The preliminary assays indicated that some of the newly obtained compounds exhibited good antitumor activities against human hepatocellular liver carcinoma (HepG2), heptoma (Huh-7), melanoma (A875) and 5-fluorouracil-resistant human hepatocellular carcinoma (BEL-7402/5-FU) cell lines compared with 5-fluorouracil (5-FU), which might be considered as promising lead scaffold for further design and synthesis of highly potential anticancer agents.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antitumor activity; Dehydroepiandrosterone; Hybrids; Isatin; Synthesis

Mesh：

Substances：

Year:  2015        PMID： 26320625     DOI： 10.1016/j.bmcl.2015.08.041

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  8 in total

1.  Design, Synthesis, Anticancer Evaluation, Enzymatic Assays, and a Molecular Modeling Study of Novel Pyrazole-Indole Hybrids.

Authors:  Ashraf S Hassan; Gaber O Moustafa; Hanem M Awad; Eman S Nossier; Mohamed F Mady
Journal:  ACS Omega       Date:  2021-04-29

2.  Steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone: A convenient synthesis, antiproliferation activity, structure-activity relationships, and role of heterocyclic moiety.

Authors:  Shaoyong Ke; Liqiao Shi; Zhigang Zhang; Ziwen Yang
Journal:  Sci Rep       Date:  2017-03-14       Impact factor: 4.379

3.  Peptidomimetics Based On Dehydroepiandrosterone Scaffold: Synthesis, Antiproliferation Activity, Structure-Activity Relationship, and Mechanisms.

Authors:  Xiaohui Wang; Haihuan Su; Wenda Wang; Changshui Chen; Xiufang Cao
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

Review 4.  Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents.

Authors:  Eleni Sflakidou; George Leonidis; Eirini Foroglou; Christos Siokatas; Vasiliki Sarli
Journal:  Molecules       Date:  2022-10-06       Impact factor: 4.927

5.  Novel Thiazolidinone/Thiazolo[3,2-a]Benzimidazolone-Isatin Conjugates as Apoptotic Anti-proliferative Agents Towards Breast Cancer: One-Pot Synthesis and In Vitro Biological Evaluation.

Authors:  Mohamed El-Naggar; Wagdy M Eldehna; Hadia Almahli; Amr Elgez; Mohamed Fares; Mahmoud M Elaasser; Hatem A Abdel-Aziz
Journal:  Molecules       Date:  2018-06-12       Impact factor: 4.411

6.  Investigations on Anticancer Potentials by DNA Binding and Cytotoxicity Studies for Newly Synthesized and Characterized Imidazolidine and Thiazolidine-Based Isatin Derivatives.

Authors:  Nasima Arshad; Muhammad Ismail Mir; Fouzia Perveen; Aneela Javed; Memona Javaid; Aamer Saeed; Pervaiz Ali Channar; Shahid Iqbal Farooqi; Saad Alkahtani; Jamshed Anwar
Journal:  Molecules       Date:  2022-01-06       Impact factor: 4.411

7.  Anticancer Effects with Molecular Docking Confirmation of Newly Synthesized Isatin Sulfonamide Molecular Hybrid Derivatives against Hepatic Cancer Cell Lines.

Authors:  Mahmoud Eldeeb; Eman F Sanad; Ahmed Ragab; Yousry A Ammar; Khaled Mahmoud; Mamdouh M Ali; Nadia M Hamdy
Journal:  Biomedicines       Date:  2022-03-20

Review 8.  Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery.

Authors:  Rameshwar S Cheke; Vaishali M Patil; Sandip D Firke; Jaya P Ambhore; Iqrar A Ansari; Harun M Patel; Sachin D Shinde; Visweswara Rao Pasupuleti; Md Imtaiyaz Hassan; Mohd Adnan; Adel Kadri; Mejdi Snoussi
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.